Graft versus Leukemia in 2023

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Allogeneic hematopoietic stem cell transplantation (HSCT) is a standard treatment for various leukemia subtypes.
• The graft-versus-leukemia (GVL) effect, mediated by donor immune cells, is crucial for eliminating residual leukemia post-transplant.
• Graft-versus-host disease (GVHD) is a significant complication where donor cells attack recipient organs, leading to autoimmune-like toxicities.

Purpose of the Study:

• To review the allogeneic HSCT process, focusing on the critical interplay between the graft-versus-leukemia (GVL) effect and graft-versus-host disease (GVHD).
• To elucidate the mechanisms underlying GVL and GVHD, which are mediated by similar cellular processes.
• To provide insights into managing the dual nature of donor immune cell activity in the context of leukemia treatment.

Main Methods:

• Literature review of allogeneic HSCT, GVL, and GVHD.
• Analysis of the immunological mechanisms driving both beneficial (GVL) and detrimental (GVHD) responses.
• Synthesis of current understanding regarding the tandem occurrence of GVL and GVHD.

Main Results:

• GVL is essential for eradicating leukemia post-transplantation.
• GVHD is a frequent complication resulting from donor immune cell recognition of recipient tissues.
• GVL and GVHD are closely linked, often occurring concurrently due to shared underlying mechanisms.

Conclusions:

• The efficacy of allogeneic HSCT in leukemia management is intrinsically tied to the GVL effect.
• Managing GVHD is paramount to mitigate transplant-related toxicities while preserving the therapeutic GVL response.
• Further research into modulating donor immune cell activity is needed to optimize HSCT outcomes for leukemia patients.